MedPath

Study of the efficacy and safety of insulin degludec who treating with basal insulin glargine or insulin detemir in type 1 diabetes with the Basal-Bolus Therapy

Not Applicable
Recruiting
Conditions
Type 1 diabetes
Registration Number
JPRN-UMIN000012358
Lead Sponsor
Toho University School of Medicine, Division of diabetes, metabolism and endocrinology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Type 2 diabetes mellitus patients (2) Patients with severe liver disease (3) Patients with severe renal disease (4) Patients who had myocardial infarction within 3 months, or obvious heart failure case (5) Patients with severe pancreas disease (6) Patients having a cancer (7) Patients with hemoglobin (Hb) less than 11 g/dL (8) Patients that the number of the platelets is less than 100,000 /mm3 (9) Patients with high diabetic neuropathy (10) Patients having a proliferative retinopathy (11) Patients with a serious infectious disease or a serious injury (12) Patients with bowel disease or ileus factors (13) Chronic enteropathy patients with the digestion and absorption abnormality (14) Excessive common custom drinker (15) A pregnant woman or the woman who may be pregnant (16) Patients who was infected with hepatitis B virus or hepatitis C virus (17) In addition, the patient who judged inappropriate by an attendant physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Daily glucose fluctuation (MAGE,SD), incidence of hypoglycemia, change of QOL,change of HbA1c
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath